Public Employees Retirement Association of Colorado held its stake in Radius Health, Inc. (NASDAQ:RDUS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,992 shares of the biopharmaceutical company’s stock at the end of the second quarter. Public Employees Retirement Association of Colorado’s holdings in Radius Health were worth $316,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Radius Health by 98,245.6% in the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after buying an additional 2,628,070 shares during the last quarter. Credit Agricole S A purchased a new position in shares of Radius Health during the first quarter worth $10,026,000. BB Biotech AG boosted its position in shares of Radius Health by 4.1% in the first quarter. BB Biotech AG now owns 4,540,399 shares of the biopharmaceutical company’s stock worth $175,486,000 after buying an additional 180,000 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Radius Health by 67.8% in the first quarter. Bank of New York Mellon Corp now owns 444,049 shares of the biopharmaceutical company’s stock worth $17,163,000 after buying an additional 179,471 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Radius Health by 3.2% in the first quarter. Vanguard Group Inc. now owns 3,010,646 shares of the biopharmaceutical company’s stock worth $116,362,000 after buying an additional 93,188 shares in the last quarter.

Radius Health, Inc. (RDUS) opened at 37.61 on Wednesday. Radius Health, Inc. has a 1-year low of $31.58 and a 1-year high of $59.22. The company’s market cap is $1.64 billion. The stock has a 50 day moving average price of $40.73 and a 200-day moving average price of $39.89.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.35) by $0.23. The business had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same period in the previous year, the business posted ($1.01) earnings per share. On average, equities research analysts forecast that Radius Health, Inc. will post ($5.51) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/30/radius-health-inc-rdus-position-maintained-by-public-employees-retirement-association-of-colorado.html.

Several equities analysts recently issued reports on RDUS shares. Cowen and Company lowered Radius Health from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 2nd. Jefferies Group LLC cut their price objective on Radius Health from $40.00 to $34.00 and set a “hold” rating on the stock in a research report on Tuesday, May 2nd. Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a research report on Thursday, May 4th. HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Radius Health in a research report on Friday, May 5th. Finally, Canaccord Genuity restated a “buy” rating and set a $85.00 price target on shares of Radius Health in a research report on Monday, May 22nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $53.60.

In related news, major shareholder Growth N. V. Biotech purchased 150,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were bought at an average price of $34.97 per share, for a total transaction of $5,245,500.00. Following the acquisition, the insider now directly owns 5,113,799 shares in the company, valued at $178,829,551.03. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Growth N. V. Biotech purchased 60,000 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was bought at an average price of $35.98 per share, for a total transaction of $2,158,800.00. Following the acquisition, the insider now owns 5,248,799 shares in the company, valued at $188,851,788.02. The disclosure for this purchase can be found here. 15.00% of the stock is owned by corporate insiders.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.